Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has scheduled its second quarter 2025 financial results announcement for August 12, 2025.
The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Participants must pre-register at least one day in advance to receive dial-in information. The webcast will be archived for 30 days on Acumen's investor relations website.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti per la malattia di Alzheimer, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025.
L'azienda terrà una conferenza telefonica e una trasmissione audio in diretta alle 8:00 a.m. ET per discutere aggiornamenti aziendali e performance finanziarie. I partecipanti devono registrarsi almeno un giorno prima per ricevere le informazioni di accesso. La registrazione della trasmissione sarà disponibile per 30 giorni sul sito web delle relazioni con gli investitori di Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos para la enfermedad de Alzheimer, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025.
La compañía realizará una llamada conferencia y una transmisión de audio en vivo a las 8:00 a.m. ET para discutir actualizaciones comerciales y desempeño financiero. Los participantes deben registrarse con al menos un día de anticipación para recibir la información de acceso. La transmisión quedará archivada por 30 días en el sitio web de relaciones con inversionistas de Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 알츠하이머병 치료제 개발에 집중하는 임상 단계 바이오제약 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 12일로 예정했습니다.
회사는 동부 표준시 기준 오전 8시에 사업 업데이트 및 재무 성과를 논의하기 위한 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다. 참가자는 접속 정보를 받기 위해 최소 하루 전에 사전 등록해야 합니다. 웹캐스트는 Acumen 투자자 관계 웹사이트에 30일간 아카이브됩니다.
Acumen Pharmaceuticals (NASDAQ : ABOS), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements contre la maladie d'Alzheimer, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 12 août 2025.
La société organisera une conférence téléphonique et une diffusion audio en direct à 8h00 ET pour discuter des mises à jour commerciales et des performances financières. Les participants doivent s'inscrire au moins un jour à l'avance pour recevoir les informations d'accès. La diffusion sera archivée pendant 30 jours sur le site des relations investisseurs d'Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien gegen Alzheimer konzentriert, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 12. August 2025 geplant.
Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz und einen Audio-Webcast abhalten, um Geschäftsaktualisierungen und finanzielle Leistungen zu besprechen. Teilnehmer müssen sich mindestens einen Tag im Voraus registrieren, um die Einwahlinformationen zu erhalten. Der Webcast wird für 30 Tage auf der Investor-Relations-Website von Acumen archiviert.
- None.
- None.
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (NASDAQ: ABOS) report Q2 2025 earnings?
How can investors access Acumen Pharmaceuticals' Q2 2025 earnings call?
What is Acumen Pharmaceuticals' main focus in drug development?
Where can investors find the replay of Acumen's Q2 2025 earnings webcast?
